Follow the IRLAB Therapeutics AB stock price and the full insider trade history of the company, a publicly traded company based in Finland. Shares are quoted on FI FI, under the oversight of FIN-FSA. Operating in the Health Care sector, IRLAB Therapeutics AB has published 7 public disclosures. Market capitalisation: €112m. The latest transaction was filed on 2 July 2026 (Purchase). Among the most active insiders: Joakim Tedroff. All data is openly available.
7
Insider Decl.
0
Thresholds
€545,299
7 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate IRLAB Therapeutics AB Strong Buy (bullish), based on 1 analysts. Average price target: SEK 7.50.
37Σ signal
Buys €545,299· Sells
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
70,000 shares@ €0.18160.012% mcap21.8% of flowAktieFI:A003U002-1
Ideal exit: 17 Aug 2026 (T+270)
7 of 7 declarations
About IRLAB Therapeutics AB
IRLAB Therapeutics AB is a Swedish biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It is listed on the Stockholm Stock Exchange (XSTO).